Multiply Labs, a San Francisco-based biomanufacturing startup, announced on October 6, 2026 a $75 million Series B funding round to scale its robotic platform for producing cell and gene therapies and other advanced biologics. The round included participation from AstraZeneca, Lingotto, Strange Ventures, and returning investors Casdin Capital and Lux Capital, bringing the company’s total funding to over $100 million. Multiply Labs’ enclosed robotic clusters automate repetitive, time-sensitive steps in biologics manufacturing, and the company plans to use the new capital to expand manufacturing capacity and grow its engineering and regulatory teams.
